Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384037 | 0.82 | ACHE (0.42) | ACHEDAONFE2L2 | |
| SCHEMBL4549537 | 0.81 | ACHE (0.39) | ACHEDAO | |
| SCHEMBL8428973 | 0.81 | ACHE (0.39) | ACHEHDAC4CES2CES1 | |
| SCHEMBL5399321 | 0.77 | ACHE (0.31) | ACHE | |
| SCHEMBL112218 | 0.77 | HDAC4 (0.36) | ACHEHDAC4CES2CES1 | |
| SCHEMBL23010918 | 0.77 | ACHE (0.31) | ACHE | |
| SCHEMBL584965 | 0.77 | KDM1A (0.33) | ACHE | |
| SCHEMBL13755137 | 0.77 | ALDH1A1 (0.36) | ACHEHDAC4CES2CES1 | |
| SCHEMBL13212278 | 0.77 | HDAC4 (0.33) | ACHEHDAC4CES2CES1 | |
| SCHEMBL12225802 | 0.77 | RAPGEF4 (0.33) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260058204-A1 | ELECTROLYTE COMPOSITION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY CONTAINING THE SAME | HYUNDAI MOTOR CO LTD (KR) | 2026-02-26 | — | — | US | claimed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | claimed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| EP-0498724-B1 | Esters of 3-(3,3,3-trifluoro-2-chloropropenyl)-2,2-dimethyl-cyclopropanecarboxylic acid, process for their preparation and their use as pesticides | ROUSSEL UCLAF (FR) | 1996-05-15 | — | — | EP | claimed |
| EP-4732350-A2 | SYSTEMS AND METHODS FOR RECHARGEABLE ENERGY SOURCE SYSTEMS WITH DE-LITHIATED POSITIVE ELECTRODES | PURE LITHIUM CORPORATION (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260058204-A1 | ELECTROLYTE COMPOSITION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY CONTAINING THE SAME | HYUNDAI MOTOR CO LTD (KR) | 2026-02-26 | — | — | US | disclosed |
| WO-2025231187-A1 | LITHIUM METAL ELECTRODE AND BATTERY | Pure Lithium Corporation (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250270725-A1 | CROWN ETHER LIQUID-LIQUID EXTRACTION SYSTEM FOR THE ELECTRODEPOSITION OF LITHIUM METAL FROM BRINE | Pure Lithium Corporation | 2025-08-28 | — | — | US | disclosed |
| US-12388086-B2 | ϵ-VOPO4 cathode for lithium ion batteries | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4590876-A1 | CROWN ETHER LIQUID-LIQUID EXTRACTION SYSTEM FOR THE ELECTRODEPOSITION OF LITHIUM METAL FROM BRINE | PURE LITHIUM CORPORATION (US) | 2025-07-30 | — | — | EP | disclosed |
| US-5591744-A | 1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLATE DERIVATIVES; MICROBIOCIDES | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-01-07 | — | — | US | disclosed |
| EP-0287951-B1 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5495020-A | CHEMICAL INTERMEDIATE FOR BACTERICIDES, MICROBIOCIDES, DISINFECTANTS; SIDE EFFECT REDUCTION, ABSORPTION | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-02-27 | — | — | US | disclosed |
| US-5340835-A | Insecticides | ROUSSEL-UCLAF (FR) | 1994-08-23 | — | — | US | disclosed |
| US-5336670-A | 2,2-dimethyl-3-(but-1-en-3-ynyl)-cyclopropane carboxylates | ROUSSEL-UCLAF (FR) | 1994-08-09 | — | — | US | disclosed |
| EP-0565132-A2 | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260058204-A1 | ELECTROLYTE COMPOSITION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY CONTAINING THE SAME | KCNN2, DYRK1B, SETDB1 | ACHE 1953/4885HDAC4 3018/4885CES2 2767/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | ACHE 2534/4885HDAC4 3031/4885CES2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.